A new research done among Hispanic and non-Hispanic whites showed that the drug ranibizumab, prescribed to treat age-related vision loss or macular degeneration also reverses vision lost by diabetes.
Diabetic retinopathy and diabetic macular edema are the leading causes of vision loss in working-age adults in the United States, according to the National Eye Institute.
Fish Oil Supplements May Not Prevent Blindness: NIH Study
Fish oil pills are believed to prevent macular degeneration, instead a diet rich in fruits, vegetables, meat and whole grains can improve your vision.
Advertisement
Laser surgery is the standard treatment for advanced stages of the disease, characterized by blurred vision, but previous research has shown that only 30 percent of patients saw improvement in their vision.
Lead author Rohit Varma from the University of Southern California (USC) Eye Institute said that found that ranibizumab can save the sight of thousands of working-age individuals suffering from diabetic eye disease, as standard treatments such as laser are not as effective.
![Diabetic Retinopathy]( "Diabetic Retinopathy")
The term 'diabetic retinopathy' refers to changes in the retina which often occur in people with diabetes.
Varma's team developed a population-based model that suggests that administering 0.3 milligrams of ranibizumab every four weeks to patients with diabetic macular edema would reduce the number of cases of vision impairment by 45 percent, or 5,134 individuals, and the number of cases of legal blindness by 75 percent, or 1,275 individuals.
The model was based on the approximately 37,000 Hispanic and non-Hispanic white adults with diabetic macular edema in the United States for whom ranibizumab treatment could be used and because other race and ethnic groups were not included in the study, authors contend that the treatment may benefit even more people than their results show.
It appears in the online edition of journal Ophthalmology.
Source: ANI
Diabetic Retinopathy
The term 'diabetic retinopathy' refers to changes in the retina which often occur in people with diabetes.
Advertisement
Varma's team developed a population-based model that suggests that administering 0.3 milligrams of ranibizumab every four weeks to patients with diabetic macular edema would reduce the number of cases of vision impairment by 45 percent, or 5,134 individuals, and the number of cases of legal blindness by 75 percent, or 1,275 individuals.
The model was based on the approximately 37,000 Hispanic and non-Hispanic white adults with diabetic macular edema in the United States for whom ranibizumab treatment could be used and because other race and ethnic groups were not included in the study, authors contend that the treatment may benefit even more people than their results show.
It appears in the online edition of journal Ophthalmology.
Source: ANI
Even Expert Searchers Struggle With Inattentive Blindness, Suggests Study
Researcher suggest that even expert searchers struggle with inattentional blindness, where people fail to see an unexpected stimulus in their field of vision if they are not looking for it.
Advertisement
 World Sight Day 2014: No More Avoidable BlindnessThe World Sight Day 2014 will be observed on the 9th of October with the theme: No More Avoidable Blindness. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.